NCT07377539
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants
StatusActive, Not Recruiting
PhasePhase 1
SponsorJazz Pharmaceuticals
Primary completion (estimated)
At risk: Primary completion moved at least 4 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 17 words Show 4 more changesShow less
- Enrollment closed, study ongoing
- Primary and study completion pushed from Jul 5, 2026 to Nov 30, 2026
- Study description revised
- Site details revised
- Notable Recruitment opened
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Number of Participants Reporting Treatment-emergent Adverse Events (Part A)
Timeframe: Baseline up to Day 90
Number of Participants Reporting Treatment-emergent Adverse Events (Part B)
Timeframe: Baseline up to Day 90
Number of Participants Who Discontinued The Study (Part A)
Timeframe: Baseline up to Day 90
Number of Participants Who Discontinued The Study (Part B)
Timeframe: Baseline up to Day 90
Pharmacokinetic Parameter Maximum Concentration (Part A)
Timeframe: Up to 90 days
Pharmacokinetic Parameter Time to Maximum Concentration and Time Before the Start of Absorption (Part A)
Timeframe: Up to 90 days
Pharmacokinetic Parameter Terminal Elimination Half-life (Part A)
Timeframe: Up to 90 days
Pharmacokinetic Parameter Terminal Elimination Rate Constant (Part A)
Timeframe: Up to 90 days
Pharmacokinetic Parameter Volume of Distribution During Terminal Phase (Part A)
Timeframe: Up to 90 days
Pharmacokinetic Parameter Oral Clearance (Part A)
Timeframe: Up to 90 days
Pharmacokinetic Parameter Area Under the Concentration-Time Curve (Part A)
Timeframe: Up to 90 days
Pharmacokinetic Parameter Percentage of The Area Under the Concentration-Time Curve From Time Infinity Due to Extrapolation From The Last Quantifiable Concentration to Time Infinity (Part A)
Timeframe: Up to 90 days
Secondary (4)
Dose Proportionality of JZP047 Cmax (Part A)
Dose Proportionality of JZP047 AUC0-last and AUC∞
The Effect of Food On The Single Dose PK of JZP047 Cmax
The Effect of Food On The Single Dose PK of JZP047 AUC0-last and AUC∞
Arms and interventions
Part A: JZP047Experimental
Healthy participants who are randomized to JZP047.
Part A: PlaceboPlacebo comparator
Healthy participants who are randomized to placebo.
Part B: JZP047Experimental
Healthy participants who will receive JZP047.
Drugs: JZP047
Other: Placebo
Sites
1 site in 1 country
- Celerion, Inc.Lincoln, Nebraska, United States